PMID- 31129419
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20231213
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 73
DP  - 2019 Aug
TI  - Molecular mechanism underlying anti-inflammatory activities of lirioresinol B 
      dimethyl ether through suppression of NF-kappaB and MAPK signaling in in vitro and in 
      vivo models.
PG  - 321-332
LID - S1567-5769(19)30639-3 [pii]
LID - 10.1016/j.intimp.2019.05.020 [doi]
AB  - The aim of the present study is to explore the anti-inflammatory mechanism of 
      lirioresinol B dimethyl ether via inhibition of multiple signaling pathways in 
      both in vitro and in vivo pharmacological models. To determine the 
      anti-inflammatory activity of the lirioresinol B dimethyl ether, RAW 264.7 
      macrophages challenged with lipopolysaccharide (LPS) were treated with various 
      concentrations of lirioresinol B dimethyl ether (5, 15, 25, and 50 muM). The 
      results indicated that pretreatment with lirioresinol B dimethyl ether 
      significantly suppressed nuclear factor kappa B (NF-kappaB) activation, nitric oxide 
      (NO) production, the protein expressions of inducible nitric oxide synthase 
      (iNOS) and cyclooxygenase-2 (COX-2). Lirioresinol B dimethyl ether inhibited 
      LPS-induced activation of production of pro-inflammatory cytokines as well as 
      prostaglandin E(2) (PGE(2)) release. The results obtained by electrophoretic 
      mobility shift assay (EMSA) demonstrated a concentration dependent reduction of 
      the LPS-stimulated activation of NF-kappaB and activator protein-1 (AP-1) by 
      lirioresinol B dimethyl ether in in vitro and in vivo models. Moreover, 
      lirioresinol B dimethyl ether also reduced the expression of toll-like receptor 
      (TLR)-4 protein and myeloid differentiation primary response gene 88 (MyD88) as 
      well as promoted the degradation of IkappaBalpha. Lirioresinol B dimethyl ether also 
      significantly down-regulated the phosphorylation of Jun N-terminal kinase (JNK), 
      p-38 and extracellular signal-regulated kinase (ERK). Furthermore, the results of 
      acute and chronic inflammation demonstrated that lirioresinol B dimethyl ether 
      (10 and 50 mg per kg) reduced paw edema and mechanical hyperalgesia in 
      carrageenan- and Complete Freund's Adjuvant (CFA)-induced in vivo mouse models, 
      respectively. Hence, the current results indicate that lirioresinol B dimethyl 
      ether either act by inhibiting pro-inflammatory mediators through down-regulation 
      of mitogen activated protein kinases (MAPKs) signaling pathways and reduction of 
      NF-kappaB activation.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Su, Yunshu
AU  - Su Y
AD  - Department of Cardiothorasic and Vascular Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR 
      China. Electronic address: micxu@163.com.
FAU - Xiong, Sizheng
AU  - Xiong S
AD  - Department of Cardiothorasic and Vascular Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR 
      China.
FAU - Lan, Hongwen
AU  - Lan H
AD  - Department of Cardiothorasic and Vascular Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR 
      China.
FAU - Xu, Lijun
AU  - Xu L
AD  - Department of Cardiothorasic and Vascular Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR 
      China. Electronic address: n803ve@163.com.
FAU - Wei, Xiang
AU  - Wei X
AD  - Department of Cardiothorasic and Vascular Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR 
      China. Electronic address: xiangwei201808@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190523
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Furans)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (lirioresinol B dimethyl ether)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9000-07-1 (Carrageenan)
RN  - 9007-81-2 (Freund's Adjuvant)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Carrageenan
MH  - Cell Survival/drug effects
MH  - Cytokines/metabolism
MH  - Dinoprostone/metabolism
MH  - Edema/chemically induced/drug therapy
MH  - Freund's Adjuvant
MH  - Furans/*pharmacology/therapeutic use
MH  - Hyperalgesia/chemically induced/drug therapy
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Mice
MH  - Mitogen-Activated Protein Kinases/*metabolism
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - RAW 264.7 Cells
MH  - Signal Transduction/drug effects
MH  - NF-kappaB-Inducing Kinase
OTO - NOTNLM
OT  - Anti-inflammatory
OT  - Carrageenan
OT  - Lirioresinol B dimethyl ether
OT  - MAPKs/AP-1
OT  - NF-kappaB
EDAT- 2019/05/28 06:00
MHDA- 2020/01/29 06:00
CRDT- 2019/05/27 06:00
PHST- 2019/03/26 00:00 [received]
PHST- 2019/04/15 00:00 [revised]
PHST- 2019/05/10 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2019/05/27 06:00 [entrez]
AID - S1567-5769(19)30639-3 [pii]
AID - 10.1016/j.intimp.2019.05.020 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Aug;73:321-332. doi: 10.1016/j.intimp.2019.05.020. Epub 
      2019 May 23.